Analysts Set Annexon, Inc. (NASDAQ:ANNX) PT at $15.80

Annexon, Inc. (NASDAQ:ANNX) has earned an average rating of “Buy” from the six ratings firms that are currently covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $15.80.

Several brokerages recently commented on ANNX. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Annexon in a report on Tuesday, August 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Annexon in a report on Tuesday, August 13th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a report on Monday, September 9th.

Insider Activity

In related news, EVP Ted Yednock sold 5,500 shares of the business’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $5.64, for a total value of $31,020.00. Following the sale, the executive vice president now directly owns 10,000 shares in the company, valued at approximately $56,400. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 20,908 shares of company stock worth $135,768 over the last ninety days. Corporate insiders own 12.67% of the company’s stock.

Institutional Investors Weigh In On Annexon

A number of hedge funds have recently made changes to their positions in the company. Bain Capital Life Sciences Investors LLC lifted its position in shares of Annexon by 8.0% in the first quarter. Bain Capital Life Sciences Investors LLC now owns 8,703,268 shares of the company’s stock worth $62,402,000 after buying an additional 641,549 shares in the last quarter. Point72 Asset Management L.P. increased its stake in Annexon by 16.1% during the second quarter. Point72 Asset Management L.P. now owns 5,989,017 shares of the company’s stock worth $29,346,000 after acquiring an additional 832,617 shares during the last quarter. Vanguard Group Inc. increased its stake in Annexon by 96.4% during the first quarter. Vanguard Group Inc. now owns 3,747,655 shares of the company’s stock worth $26,871,000 after acquiring an additional 1,839,329 shares during the last quarter. Bellevue Group AG bought a new stake in Annexon during the first quarter worth approximately $15,647,000. Finally, Candriam S.C.A. bought a new stake in Annexon during the second quarter worth approximately $10,061,000.

Annexon Price Performance

Shares of ANNX opened at $7.48 on Monday. Annexon has a one year low of $1.67 and a one year high of $8.40. The firm has a market capitalization of $691.25 million, a P/E ratio of -5.09 and a beta of 1.28. The business has a fifty day moving average of $6.37 and a 200 day moving average of $5.67.

Annexon (NASDAQ:ANNX) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.23) EPS for the quarter, hitting the consensus estimate of ($0.23). Analysts expect that Annexon will post -0.97 EPS for the current fiscal year.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.